Get the Stockscreener App
37.61
1.65%
0.61
Pre-market:
36.13
-1.48
-3.94%
Korro Bio Inc stock is traded at $37.61, with a volume of 46,176.
It is up +1.65% in the last 24 hours and down -13.88% over the past month.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.
See More
Previous Close:
$37.00
Open:
$37.79
24h Volume:
46,176
Relative Volume:
0.32
Market Cap:
$352.34M
Revenue:
-
Net Income/Loss:
$-81.17M
P/E Ratio:
-3.7111
EPS:
-10.1344
Net Cash Flow:
$-82.84M
1W Performance:
+1.62%
1M Performance:
-13.88%
6M Performance:
-17.47%
1Y Performance:
-8.49%
1-Day Range:
$37.00
$38.46
1-Week Range:
$36.02
$38.59
52-Week Range:
$30.00
$98.00
Korro Bio Inc Stock (KRRO) Company Profile
Name
Korro Bio Inc
Sector
Industry
Phone
617-468-1999
Address
60 FIRST STREET, CAMBRIDGE
Compare KRRO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KRRO
Korro Bio Inc
|
37.61 | 352.34M | 0 | -81.17M | -82.84M | -10.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Korro Bio Inc Stock (KRRO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-10-25 | Initiated | Oppenheimer | Outperform |
| Oct-21-24 | Initiated | Raymond James | Strong Buy |
| Aug-14-24 | Initiated | William Blair | Outperform |
| Mar-28-24 | Reiterated | H.C. Wainwright | Buy |
| Feb-27-24 | Initiated | BMO Capital Markets | Outperform |
| Dec-04-23 | Initiated | H.C. Wainwright | Buy |
| Nov-29-23 | Initiated | RBC Capital Mkts | Outperform |
| Nov-10-23 | Initiated | Piper Sandler | Overweight |
| Feb-15-23 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Feb-13-23 | Downgrade | Cowen | Outperform → Market Perform |
| Sep-22-21 | Downgrade | Goldman | Buy → Neutral |
| Jan-27-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-22-20 | Initiated | B. Riley Securities | Buy |
| Jul-14-20 | Initiated | Oppenheimer | Outperform |
| May-18-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Oct-28-19 | Initiated | Cowen | Outperform |
| Oct-28-19 | Initiated | Goldman | Buy |
| Oct-28-19 | Initiated | JP Morgan | Overweight |
View All
Korro Bio Inc Stock (KRRO) Latest News
Korro Bio (NASDAQ:KRRO) Doses First Participants in REWRITE Phase 1/2a Clinical Study – Pipeline Update ProvidedOn January 13, 2025, Korro Bio, Inc. issued a press release stating that it had initiated dosing the first participants in its REWRITE Pha - Defense World
Korro Bio, Inc. (NASDAQ:KRRO) Short Interest Update - MarketBeat
Korro Bio Announces Dosing of First Participants in REWRITE Phase 1/2a Study of KRRO-110 for Alpha-1 Antitrypsin Deficiency - Marketscreener.com
Korro Bio Announces Dosing of First Participants in REWRITE Phase 1/2a Study of KRRO-110 for Alpha-1 Antitrypsin Deficiency and Provides Pipeline Update - The Manila Times
Korro Bio Launches First Clinical Trial for AATD Treatment KRRO-110, Marks Clinical Stage Milestone - StockTitan
Korro Bio (NASDAQ:KRRO) Research Coverage Started at Oppenheimer - Defense World
Korro Bio (NASDAQ:KRRO) Now Covered by Analysts at Oppenheimer - MarketBeat
Korro Bio CEO to Present RNA Editing Breakthroughs at JP Morgan Healthcare Conference - StockTitan
Geode Capital Management LLC Sells 2,161 Shares of Korro Bio, Inc. (NASDAQ:KRRO) - Defense World
Korro Bio, Inc. (NASDAQ:KRRO) Receives Average Rating of “Buy” from Analysts - Defense World
Korro Bio, Inc. (NASDAQ:KRRO) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
Korro Bio, Inc. (NASDAQ:KRRO) Stock Position Increased by State Street Corp - MarketBeat
State Street Corp Acquires 18,877 Shares of Korro Bio, Inc. (NASDAQ:KRRO) - Defense World
Korro Bio: Still Too Long To Go… Just Keep Watching For Now (Rating Upgrade) (NASDAQ:KRRO) - Seeking Alpha
Wellington Management Group LLP Invests $436,000 in Korro Bio, Inc. (NASDAQ:KRRO) - MarketBeat
Frequency Therapeutics : The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Frequency Therapeutics, Inc. (FREQ) Investors - Marketscreener.com
BNP Paribas Financial Markets Purchases 4,470 Shares of Korro Bio, Inc. (NASDAQ:KRRO) - Defense World
Korro Bio's SWOT analysis: RNA editing pioneer's stock poised for clinical catalyst - Investing.com Nigeria
Fmr LLC Has $19.37 Million Holdings in Korro Bio, Inc. (NASDAQ:KRRO) - MarketBeat
Why Korro Bio (KRRO) Should Be on Your Investment Radar - Nasdaq
Korro Bio, Inc. (NASDAQ:KRRO) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
100-employee biotech opens new Kendall Square HQ - The Business Journals
Verition Fund Management LLC Has $3.12 Million Stake in Korro Bio, Inc. (NASDAQ:KRRO) - MarketBeat
Korro Bio to Begin RNA-Editing Trial in Alpha-1 Antitrypsin Deficiency - CRISPR Medicine News
Korro Bio, Inc. (NASDAQ:KRRO) Short Interest Down 6.5% in November - Defense World
Quest Partners LLC Has $59,000 Stock Position in Korro Bio, Inc. (NASDAQ:KRRO) - Defense World
Eventide Asset Management LLC Sells 137,989 Shares of Korro Bio, Inc. (NASDAQ:KRRO) - MarketBeat
We Think Korro Bio (NASDAQ:KRRO) Needs To Drive Business Growth Carefully - Simply Wall St
Korro Bio, Inc Receives Approval from the Australian Bellberry Human Research Ethics Committee and Clearance from the Australian Therapeutic Goods Administration to Initiate A Phase 1/2A Clinical Study of KRRO-110 for Alpha-1 Antitrypsin Deficiency - Marketscreener.com
Korro Bio's SWOT analysis: RNA editing stock poised for growth amid AATD treatment race - Investing.com
HC Wainwright Reaffirms Buy Rating for Korro Bio (NASDAQ:KRRO) - Defense World
Korro Bio (NASDAQ:KRRO) Trading 9.3% HigherHere's What Happened - MarketBeat
Korro Bio (NASDAQ:KRRO) Receives Buy Rating from HC Wainwright - MarketBeat
Korro secures approvals in Australia to commence AATD trial of KRRO-110 - Yahoo Finance
Korro to Participate in Upcoming Investor Conferences - The Manila Times
Korro Bio CEO to Present at Major Healthcare Conferences in December | KRRO Stock News - StockTitan
Korro Receives Australian HREC Approval and CTN Clearance to Initiate Phase 1/2a Clinical Study (REWRITE) of KRRO-110 for Alpha-1 Antitrypsin Deficiency - The Manila Times
Korro Bio Gains Approval for Phase 1/2a AATD Treatment Trial, Shows Strong Preclinical Data | KRRO Stock News - StockTitan
Jones Trading bullish on Korro Bio stock amid RNA editing and AATD prospects - Investing.com
This TechnipFMC Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Korro Bio FY2024 EPS Forecast Increased by HC Wainwright - MarketBeat
William Blair Has Positive View of Korro Bio FY2024 Earnings - MarketBeat
Jones Trading Initiates Coverage of Korro Bio (KRRO) with Buy Recommendation - MSN
Korro Bio, Inc. (NASDAQ:KRRO) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Eventide Asset Management's Strategic Reduction in Korro Bio Inc Holdings - GuruFocus.com
Deep Track Capital, LP's Strategic Acquisition of Korro Bio Inc Shares - GuruFocus.com
Korro to Present at the Jefferies London Healthcare Conference - The Manila Times
Korro Bio to Present RNA-Editing Breakthroughs at Jefferies London Healthcare Conference | KRRO Stock News - StockTitan
Korro Bio’s Progress and Financial Updates - TipRanks
Korro Bio's SWOT analysis: RNA editing pioneer's stock poised for growth - Investing.com
William Blair Reiterates "Outperform" Rating for Korro Bio (NASDAQ:KRRO) - MarketBeat
Korro Bio Inc Stock (KRRO) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):